FOLD News and Press, Amicus Therapeutics Inc. From 08/21/23

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has b...

2023-08-15 08:34:15 ET More on Amicus Therapeutics Amicus Therapeutics Inc. ( FOLD ) Q2 2023 Earnings Call Transcript Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive Amicus Therapeutics reports mixed Q2 earnings; updates FY23 outlook ...

Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation ...

2023-08-08 15:29:06 ET Amicus Therapeutics Inc. (FOLD) Q2 2023 Results Conference Call August 08, 2023 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President, Chief Executive Officer Daphne Quimi - Chief...

2023-08-08 07:10:05 ET Amicus Therapeutics press release ( NASDAQ: FOLD ): Q2 GAAP EPS of -$0.15 misses by $0.04 . Revenue of $94.5M (+17.1% Y/Y) beats by $4.63M . Cash, cash equivalents, and marketable securities totaled $265.6 million at June 30, 2023, compar...

1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold ® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti ® + Opfolda ® Underway; U.S. and U.K. Approvals Expected...

2023-08-07 13:36:26 ET Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $89.87M (+11.4% Y/Y). Over the last 1 year, F...

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2023. Partici...

PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has granted approval for Opfolda ...

2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...